Eavesdropping in houston

Overheard: Expert panel weighs in on the future of Houston — from mobility to climate change

As the city grows, Houston faces more and more challenges from transportation and infrastructure to gentrification and climate change. Getty Images

As technology and infrastructure evolves, Houston is growing and evolving with it — in both good ways and bad.

On October 30, Gensler hosted its annual Evolution Houston forum that brings together various personalities and industries to discuss the future of the city of Houston. The panelists discussed gentrification, climate change, mobility, smart cities, and so many other hot topics Houstonians hear or think about on a regular basis.

Missed the event? Here are some powerful quotes from the discussion.

“I like to think of Houston as an adolescent city, struggling for its identity.”

Peter Merwin, design principal at Gensler, who adds, "If you look at places like New York, London, Paris — those are all luxury cities. They are fully formed, and a consequence of that is that they become unaffordable. It's something that we have to be careful about in Houston."

“One of the things that has been echoed by many of the artists and many of the poor people over the last few years is, [people] ‘want the culture but they don’t want us.’ It’s very reflective when you go [into the communities.]”

Kam Franklin, activist and singer-songwriter of The Suffers. Franklin described how she would move from the various neighborhoods she's lived in after they've grown in culture. She would see such a huge increase in her rent as people were more willing to pay the premium to live in these newly desirable neighborhoods because of the culture, but its pricing out the original inhabitants. Franklin added, "I'm not going to tell any of y'all where I moved."

“We have to continue to support the diversification of mobility options.”

Abbey Roberson, vice president of planning at the Texas Medical Center. Roberson says transportation is something she particularly focuses on considering how many people filter in and out of the TMC on a daily basis. The medical center wouldn't be able to support the traffic with out various modes of transportation — busses, light rails, etc. Roberson adds that this translates to the rest of the city. "We can't just be doing one thing or the other."

“We’re creating this great culture of trail activation.”

Steve Radom, founder & managing principal at Radom Capital LLC, which developed Heights Mercantile off a bike path and is now building out The MKT, which is also along the same bike path. Radom notes that the city has seen a 300 percent year over year in walkability and a 70 percent increase in bike traffic.

“Climate change is not something the city of Houston can change alone.”

Lara Cottingham, chief of staff & chief sustainability officer at the city of Houston. The city's climate action plan is a result of the devastating floods has seen almost annually. The plan is still being drafted but a version is expected to be released before the end of the year. Every city is facing sustainability challenges, and partnerships are what's going to drive change. "In Houston success means partnership," Cottingham adds.

“How do you talk about a city this big and diverse — every neighborhood has its own identity.”

Jon Nordby, managing director of MassChallenge in Houston, discussed how Houston functions differently from other cities in that it its various neighborhoods — the Heights, Montrose, downtown — are different from each other.

Trending News

Building Houston

 
 

InformAI has three AI-based products geared at improving health care. Photo via Getty Images

In Houston, we’re lucky to have top-tier doctors in the Texas Medical Center, ready to treat us with the newest technology. But what about our family members who have to rely on rural hospitals? Thanks to one Houston company, doctors in smaller community hospitals may soon have new tools at their disposal that could improve outcomes for patients around the world.

Since InnovationMap last caught up with Jim Havelka, CEO of InformAI, two years ago, that hope has come far closer to a reality. InformAI is a VC-backed digital health company. Part of JLABS @ TMC innovation facilities, the company uses artificial intelligence to develop both diagnostic tools and clinical outcome predictors. And two of the company’s products will undergo FDA regulatory testing this year.

SinusAI, which helps to detect sinus-related diseases in CT scans, received its CE Mark — the European equivalent of FDA approval — last year and is being sold across the Atlantic today, says Havelka. He adds that in the United States alone, there are roughly 700,000 sinus surgeries that the product is positioned to support.

Another product, RadOnc-AI, is designed to help doctors prescribe radiation dose plans for head and neck cancers.

“Ideally the perfect plan would be to provide radiation to the tumor and nothing around it,” says Havelka. “We’ve built a product, RadOnc-AI, which autogenerates the dose treatment plan based on medical images of that patient.”

It can be an hours-long process for doctors to figure out the path and dose of radiation themselves, but the new product “can build that initial pass in about five minutes,” Havelka says.

That in itself is an exciting development, but because this technology was developed using the expertise of some of the world’s top oncologists, “the first pass plan is in line with what [patients would] get at tier-one institutions,” explains Havelka. This creates “tremendous equity” among patients who can afford to travel to major facilities and those that can’t.

To that end, RadOnc-AI was recently awarded a $1.55 million grant from the Cancer Prevention and Research Institute of Texas, or CPRIT, a state agency that funds cancer research. The Radiological Society of North America announced late last year that InformAI was named an Aunt Minnie Best of Radiology Finalist.

“It’s quite prestigious for our company,” says Havelka. Other recent laurels include InformAI being named one of the 10 most promising companies by the Texas Life Science Forum in November.

And InformAI is only gaining steam. A third product is earlier in its stage of development. TransplantAI will optimize donor organ and patient recipient matches.

“A lot of organs are harvested and discarded,” Havelka says.

His AI product has been trained on a million donor transplants to help determine who is the best recipient for an organ. It even takes urgency into account, based on a patient’s expected mortality within 90 days. The product is currently a fully functional prototype and will soon move through its initial regulatory clearances.

The company — currently backed by three VC funds, including DEFTA Partners, Delight Ventures, and Joyance Partners — is planning to do another seed round in Q2 of 2023.

“We’ve been able to get recognized for digital health products that can be taken to market globally,” says Havelka.

But what he says he’s most excited about is the social impact of his products. With more money raised, InformAI will be able to speed up development of additional products, including expanding the cancers that the company will be targeting. And with that, more and more patients will one day be treated with the highest level of care.

Trending News